Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
Harry P. Erba(Michigan Center for Translational Pathology), Michael Andreeff(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
|JNCI Journal of the National Cancer Institute|2008|338
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment
|Blood|2012|140
The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia
|Cancer Research|2004|135
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer
|Journal of Biological Chemistry|2005|104